

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**JW (Cayman) Therapeutics Co. Ltd**

**藥明巨諾（開曼）有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2126)**

## **NOTICE OF BOARD MEETING**

The board (the “**Board**”) of directors (the “**Directors**”) of JW (Cayman) Therapeutics Co. Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board is scheduled to be held on Thursday, March 26, 2026 for the purposes of, among other matters, (i) considering and approving the annual audited consolidated results of the Group for the year ended December 31, 2025 and its publication; (ii) recommendation of a final dividend, if any; and (iii) transacting any other business.

By order of the Board  
**JW (Cayman) Therapeutics Co. Ltd**  
**藥明巨諾（開曼）有限公司\***  
**Cheng Liu**  
Chairman

Shanghai, PRC, March 11, 2026

*As at the date of this announcement, the Board comprises Dr. Cheng Liu as Chairman and non-executive Director, Mr. Tian Feng as executive Director, Dr. Yiping James Li, Ms. Xing Gao and Dr. Sungwon Song as non-executive Directors, and Mr. Kin Cheong Kelvin Ho, Dr. Debra Yu and Mr. Peng Kuan Chan as independent non-executive Directors.*

\* For identification purpose only